This episode of This Week in Virology reviews several current topics in virology and public health, followed by detailed discussions of two research papers. The hosts cover the industrialization of scientific fraud through "paper mills," a report that the FDA may not reauthorize the Pfizer COVID-19 vaccine for young children, and a draft White House report suggesting the Kennedy administration will not pursue stricter pesticide regulations.
The first paper, from Cell, investigates a strategy for a pan-betacoronavirus vaccine by identifying highly conserved T-cell epitope regions (CTERs). The study demonstrates that including CTERs from non-spike proteins, in addition to the spike protein, significantly enhances T-cell cross-reactivity across different betacoronavirus subgenera and broadens the immune coverage across diverse human HLA types.
The second paper, from Cell Reports, details the development of a potential therapeutic for herpes simplex virus (HSV). Researchers engineered potent bispecific antibodies derived from camelid nanobodies that simultaneously target two viral glycoproteins, gB and gD. This bispecific format dramatically improves the ability to block viral cell-to-cell spread. Furthermore, the antibodies were engineered to evade an HSV immune evasion mechanism. Crucially, these bispecific antibodies were shown to suppress recurrent genital herpes in a guinea pig model, demonstrating their therapeutic potential.
Virology Update: Scientific Fraud, Vaccine News, and Breakthroughs in Coronavirus and Herpesvirus Research
7:42 Scientific Fraud as an Industry: The hosts discuss an article in Science detailing how fraudulent scientific papers have become a large-scale industry. Data researchers have identified networks of authors and editors colluding to publish fake papers, often generated by "paper mills" for a fee, posing a significant pollution problem for scientific literature.
13:14 FDA May Not Reauthorize Pfizer Vaccine for Young Children: A CIDRAP report suggests the FDA may not renew the Emergency Use Authorization for Pfizer's COVID-19 vaccine for children aged 6 months to 4 years. This would leave no approved vaccine option for healthy children in this age group, as the Moderna vaccine is only approved for those with underlying health conditions.
15:41 Kennedy Administration Unlikely to Regulate Pesticides: A draft White House report, reported by the New York Times, indicates that the administration will not propose strict restrictions on pesticides or ultra-processed foods, likely due to financial influence from the agriculture and food industries.
17:15 Paper 1: T-Cells for a Pan-Betacoronavirus Vaccine: The first paper focuses on creating a broadly protective vaccine against all betacoronaviruses (including SARS-CoV-2, MERS, and common cold viruses) by targeting T-cell immunity.
23:41 Identifying Conserved T-Cell Targets (CTERs): Researchers identified "Conserved T-cell Epitope Regions" (CTERs) by finding parts of viral proteins that are both highly immunogenic (trigger a T-cell response) and conserved across different betacoronaviruses.
32:18 Including Non-Spike Proteins is Key: A major finding is that incorporating conserved T-cell epitopes from non-spike proteins (such as N, nsp12, and nsp13) significantly increases the cross-reactivity and breadth of the T-cell response against a wide range of coronaviruses.
33:37 Broader Population Coverage: Adding these non-spike epitopes also provides more than double the coverage across diverse human populations and their different HLA types, which is crucial for creating a vaccine that works for everyone.
43:52 Paper 2: A New Therapeutic for Herpes Simplex Virus (HSV): The second paper details the development of a therapeutic antibody to treat recurrent oral and genital herpes, a lifelong infection with limited treatment options.
48:34 Targeting Cell-to-Cell Spread: A key challenge in treating HSV is that the virus can spread directly between cells through tight junctions, evading antibodies in the bloodstream. The goal was to create antibodies that can block this "cell-to-cell spread" (CCS).
50:54 Using Camelid Nanobodies: Researchers started with small, versatile antibodies from an immunized alpaca ("nanobodies"), which can potentially access hard-to-reach epitopes.
54:16 Innovation with Bispecific Antibodies: The most potent antibodies were engineered into a "bispecific" format, meaning a single antibody molecule has two different arms that can grab two different viral proteins (gB and gD) at the same time. This cross-linking action dramatically increased their ability to block both viral entry and cell-to-cell spread.
1:05:51 Evading Viral Immune Evasion: The antibodies were further engineered by modifying their Fc region (the "handle") to prevent HSV's gE/gI proteins from binding to and degrading them, while still preserving some of the antibody's important immune functions.
1:12:43 Success in a Recurrent Disease Model: Critically, these engineered bispecific antibodies were shown to be highly effective at preventing lesion recurrence in a guinea pig model of genital herpes, even when treatment was started after the infection became latent. This is a significant advance over previous antibody candidates.